350 related articles for article (PubMed ID: 28277851)
21. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
[TBL] [Abstract][Full Text] [Related]
22. Treatment of MDS: something old, something new, something borrowed..
Sekeres MA
Hematology Am Soc Hematol Educ Program; 2009; ():656-63. PubMed ID: 20008251
[TBL] [Abstract][Full Text] [Related]
23. Treatment of myelodysplastic syndromes in elderly patients.
Sanchez JF
Adv Ther; 2011 Mar; 28 Suppl 2():1-9. PubMed ID: 21431504
[TBL] [Abstract][Full Text] [Related]
24. Novel therapeutic strategies: hypomethylating agents and beyond.
Santini V
Hematology Am Soc Hematol Educ Program; 2012; 2012():65-73. PubMed ID: 23233562
[TBL] [Abstract][Full Text] [Related]
25. [Current management of myelodysplastic syndromes].
Caers J; Bonnet C; Graux C; De Prijck B; Beguin Y
Rev Med Suisse; 2011 Aug; 7(306):1634, 1636-8, 1640-3. PubMed ID: 21972730
[TBL] [Abstract][Full Text] [Related]
26. Myelodysplastic Syndromes: Diagnosis and Treatment.
Steensma DP
Mayo Clin Proc; 2015 Jul; 90(7):969-83. PubMed ID: 26141335
[TBL] [Abstract][Full Text] [Related]
27. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
28. Treatment of low-risk myelodysplastic syndromes.
Santini V
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):462-469. PubMed ID: 27913517
[TBL] [Abstract][Full Text] [Related]
29. Clinical decision-making and treatment of myelodysplastic syndromes.
Hellström-Lindberg ES; Kröger N
Blood; 2023 Dec; 142(26):2268-2281. PubMed ID: 37874917
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic syndromes: what do hospitalists need to know?
Zeidan AM; Faltas B; Douglas Smith B; Gore S
J Hosp Med; 2013 Jun; 8(6):351-7. PubMed ID: 23666619
[TBL] [Abstract][Full Text] [Related]
31. The myelodysplastic syndromes: diagnosis and treatment.
Steensma DP; Bennett JM
Mayo Clin Proc; 2006 Jan; 81(1):104-30. PubMed ID: 16438486
[TBL] [Abstract][Full Text] [Related]
32. Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial.
Revicki DA; Brandenburg NA; Muus P; Yu R; Knight R; Fenaux P
Leuk Res; 2013 Mar; 37(3):259-65. PubMed ID: 23273538
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome.
Lee JH; Choi Y; Kim SD; Kim DY; Lee JH; Lee KH; Lee SM; Lee WS; Joo YD
Eur J Haematol; 2015 Jun; 94(6):546-53. PubMed ID: 25315896
[TBL] [Abstract][Full Text] [Related]
34. Established and novel agents for myelodysplastic syndromes.
Sekeres MA; Gerds AT
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):82-9. PubMed ID: 25696839
[TBL] [Abstract][Full Text] [Related]
35. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
Merkel DG; Nagler A
Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
[TBL] [Abstract][Full Text] [Related]
36. Novel agents for the management of myelodysplastic syndromes.
Meletis J; Viniou N; Terpos E
Med Sci Monit; 2006 Sep; 12(9):RA194-206. PubMed ID: 16940944
[TBL] [Abstract][Full Text] [Related]
37. Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS).
Fenaux P
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S11-5. PubMed ID: 16085012
[TBL] [Abstract][Full Text] [Related]
38. Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).
Butrym A; Lech-Maranda E; Patkowska E; Kumiega B; Bieniaszewska M; Mital A; Madry K; Torosian T; Wichary R; Rybka J; Warzocha K; Mazur G
BMC Cancer; 2015 Jul; 15():508. PubMed ID: 26152663
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
List A
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
[TBL] [Abstract][Full Text] [Related]
40. Immunomodulating drugs in myelodysplastic syndromes.
Adès L; Fenaux P
Hematology Am Soc Hematol Educ Program; 2011; 2011():556-60. PubMed ID: 22160089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
